financetom
Business
financetom
/
Business
/
Eli Lilly Reports Positive Topline Results in Phase 3 Leukemia Study
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Eli Lilly Reports Positive Topline Results in Phase 3 Leukemia Study
Sep 8, 2025 4:51 AM

07:23 AM EDT, 09/08/2025 (MT Newswires) -- Eli Lilly ( LLY ) said Monday that topline results from its phase 3 trial evaluating Jaypirca showed clinically meaningful improvement in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma without 17p deletions.

Jaypirca significantly improved progression-free survival compared to chemoimmunotherapy in treatment-naive patients, the company said.

Eli Lilly ( LLY ) added overall survival results were not yet mature but were in favor of Jaypirca.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Copyright 2023-2026 - www.financetom.com All Rights Reserved